Advertisement

Why Can’t I Just Stay on Prednisone? The Long-Term Adverse Effects of Steroids

  • Adam Schiro
  • Daniel J. SteinEmail author

Abstract

Glucocorticoids have been a mainstay of therapy for inflammatory bowel disease for many years and have proven to be very effective for inducing remission in IBD patients. However, they are fraught with many undesirable side effects that make their long-term use problematic. This chapter reviews the data behind how glucocorticoids can be effective in IBD and also reviews the many different side effects that come with both long-term and short-term usage.

Keywords

Glucocorticoids Ulcerative colitis Crohn’s disease Osteoporosis Infection Acne Diabetes Hypertension Obesity 

References

  1. 1.
    Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Br Med J. 1955;2:1041–8.CrossRefPubMedCentralPubMedGoogle Scholar
  2. 2.
    Lennard-Jones JE, Longmore AJ, Newell AC, Wilson CW, Jones FA. An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis. Gut. 1960;1:217–22.CrossRefPubMedCentralPubMedGoogle Scholar
  3. 3.
    Summers RW, Switz DM, Sessions Jr JT, Becktel JM, Best WR, et al. National Cooperative Crohn’s Disease Study: results of drug treatment. Gastroenterology. 1979;77:847–69.PubMedGoogle Scholar
  4. 4.
    Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, et al. European Cooperative Crohn’s Disease Study (ECCDS): results of drug treatment. Gastroenterology. 1984;86:249–66.PubMedGoogle Scholar
  5. 5.
    Modigliani R, Mary JY, Simon JF, Cortot A, Soule JC, et al. Clinical, biological, and endoscopic picture of attacks of Crohn’s disease. Evolution on prednisolone. Groupe d’Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology. 1990;98:811–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Steinhart A, Ewe K, Griffiths AM, Modigliani R, Thomsen OO. Glucocorticoids for maintenance of remission in Crohn’s disease. Cochrane Database Syst 2003;Rev 4:CD000301.Google Scholar
  7. 7.
    Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621–30.CrossRefPubMedGoogle Scholar
  8. 8.
    Travis SP, Strange EF, Lémann M, Oresland T, Bemelman W, et al. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohns Colitis. 2008;2:24–62.CrossRefPubMedGoogle Scholar
  9. 9.
    Dignass A, European Crohn’s and Colitis Organisation (ECCO), et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis. 2010;4:28–62.CrossRefPubMedGoogle Scholar
  10. 10.
    Saag KG et al. Low dose long-term glucocorticoid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med. 1994;96(2):115–23.CrossRefPubMedGoogle Scholar
  11. 11.
    Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004;141(10):764–70.CrossRefPubMedGoogle Scholar
  12. 12.
    Christiansen CF et al. Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case-control study. Arch Intern Med. 2009;169(18):1677–83.CrossRefPubMedGoogle Scholar
  13. 13.
    Boscaro M et al. Hypertension in Cushing’s syndrome. In: Lundecke DK, Chrousos GP, Tolis G, editors. ACTH, Cushing’s syndrome and other hypercortisolemic states. New York, NY: Raven; 1990. p. 203–10.Google Scholar
  14. 14.
    Whitworth JA. Mechanisms of glucocorticoid-induced hypertension. Kidney Int. 1987;31(5):1213–24.CrossRefPubMedGoogle Scholar
  15. 15.
    Panthakalam S, Bhatnagar D, Klimiuk P. The prevalence and management of hyperglycaemia in patients with rheumatoid arthritis on glucocorticoid therapy. Scott Med J. 2004;49(4):139–41.PubMedGoogle Scholar
  16. 16.
    Gurwitz JH et al. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med. 1994;154(1):97.CrossRefPubMedGoogle Scholar
  17. 17.
    Curtis JR et al. Population‐based assessment of adverse events associated with long‐term glucocorticoid use. Arthritis Care Res. 2006;55(3):420–6.CrossRefGoogle Scholar
  18. 18.
    Mazziotti G et al. Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol Metab. 2006;17(4):144–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Canalis E. Mechanisms of glucocorticoid action in bone. Curr Osteoporos Rep. 2005;3(3):98–102.CrossRefPubMedGoogle Scholar
  20. 20.
    O’Brien CA et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology. 2004;145(4):1835–41.CrossRefPubMedGoogle Scholar
  21. 21.
    Manelli F, Giustina A. Glucocorticoid-induced osteoporosis. Trends Endocrinol Metab. 2000;11(3):79–85.CrossRefPubMedGoogle Scholar
  22. 22.
    Huybers S et al. Prednisolone-induced Ca2+ malabsorption is caused by diminished expression of the epithelial Ca2+ channel TRPV6. Am J Physiol Gastrointest Liver Physiol. 2007;292(1):G92–7.CrossRefPubMedGoogle Scholar
  23. 23.
    Canalis E et al. Perspectives on glucocorticoid-induced osteoporosis. Bone. 2004;34(4):593–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology. 2003;124(3):795–841.CrossRefPubMedGoogle Scholar
  25. 25.
    Kumagai S et al. Vertebral fracture and bone mineral density in women receiving high dose glucocorticoids for treatment of autoimmune diseases. J Rheumatol. 2005;32(5):863–9.PubMedGoogle Scholar
  26. 26.
    Gore DC et al. Acute response of human muscle protein to catabolic hormones. Ann Surg. 1993;218(5):679.CrossRefPubMedCentralPubMedGoogle Scholar
  27. 27.
    Klingenstein G et al. Inflammatory bowel disease related osteonecrosis: report of a large series with a review of the literature. Aliment Pharmacol Ther. 2005;21(3):243–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Messer J et al. Association of adrenoglucocorticoid therapy and peptic-ulcer disease. N Engl J Med. 1983;309(1):21–4.CrossRefPubMedGoogle Scholar
  29. 29.
    Piper JM et al. Glucocorticoid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1991;114(9):735–40.CrossRefPubMedGoogle Scholar
  30. 30.
    Starkman MN. Neuropsychiatric findings in Cushing syndrome and exogenous glucocorticoid administration. Endocrinol Metab Clin N Am. 2013;42(3):477–88.CrossRefGoogle Scholar
  31. 31.
    Toruner M et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134(4):929–36.CrossRefPubMedGoogle Scholar
  32. 32.
    Aberra FN et al. Glucocorticoids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology. 2003;125(2):320–7.CrossRefPubMedGoogle Scholar
  33. 33.
    Fardet L et al. Corticosteroid‐induced clinical adverse events: frequency, risk factors and patient’s opinion. Br J Dermatol. 2007;157(1):142–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Division of Gastroenterology and HepatologyMedical College of WisconsinMilwaukeeUSA

Personalised recommendations